Ir al contenido

Talasemia beta mayor

Riesgos e incertidumbres de las transfusiones

Seropositivity of hepatitis C, hepatitis B and HIV in chronically transfused β-thalassaemia major patients. (abre una nueva ventana)

Ansari SH, Shamsi TS, Khan MT, Perveen K, Farzana T, Erum S, Ansari I.

Fuente‎: J Coll Physicians Surg Pak 2012;22(9):610-1.

Indexado en‎: PubMed 22980623

DOI‎: 09.2012/JCPSP.610611

https://www.ncbi.nlm.nih.gov/pubmed/22980623 (abre una nueva ventana)

Clinical outcome of frequent exposure to Torque Teno virus (TTV) through blood transfusion in thalassemia patients with or without hepatitis C virus (HCV) infection. (abre una nueva ventana)

Hu YW, Al-Moslih MI, Al Ali MT, Uzicanin S, Perkins H, Yi QL, Rahimi Khameneh S, Wu J, Brown EG.

Fuente‎: J Med Virol 2008;80(2):365-71.

Indexado en‎: PubMed 18098140

DOI‎: 10.1002/jmv.21070

https://www.ncbi.nlm.nih.gov/pubmed/18098140 (abre una nueva ventana)

Prevalence of alloimmunisation in patients with beta thalassaemia major. (abre una nueva ventana)

Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT.

Fuente‎: Blood Transfus 2012;10(3):396-7.

Indexado en‎: PubMed 22395351

DOI‎: 10.2450/2012.0072-11

https://www.ncbi.nlm.nih.gov/pubmed/22395351 (abre una nueva ventana)

Marseillevirus prevalence in multitransfused patients suggests blood transmission. (abre una nueva ventana)

Popgeorgiev N, Colson P, Thuret I, Chiarioni J, Gallian P, Raoult D, Desnues C.

Fuente‎: J Clin Virol 2013;58(4):722-5.

Indexado en‎: PubMed 24183312

DOI‎: 10.1016/j.jcv.2013.10.001

https://www.ncbi.nlm.nih.gov/pubmed/24183312 (abre una nueva ventana)